<PAGE>
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
1998
FORM 10 - Q
For the Fiscal
THIRD QUARTER
Ended October 3, 1998
Quarterly Report Pursuant To Section 13 or 15(d)
of the Securities Exchange Act of 1934
MOORE MEDICAL CORP.
(Exact name of registrant as specified in its charter)
- --------------------------------------------------------------------------------
DELAWARE 1-8903
(State of incorporation) (Commission File Number)
P.O. BOX 1500, NEW BRITAIN, CT 06050 22-1897821
(Address of principal executive offices) (I.R.S. Employer
Identification Number)
860-826-3600
(Registrant's telephone number)
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
COMMON STOCK ($.01 PAR VALUE) AMERICAN STOCK EXCHANGE
(Title of Each Class) (Name of each exchange on which registered)
- --------------------------------------------------------------------------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding twelve months, and (2) has been subject to such filing
requirements for the past 90 days. Yes X No _____
--------
2,933,302
Number of shares of Common Stock outstanding as of November 5, 1998.
Total number of pages in the numbered original is 17
This is page 1 of 17 pages.
================================================================================
<PAGE>
MOORE MEDICAL CORP.
INDEX
<TABLE>
<CAPTION>
PAGE NO.
--------
<S> <C>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Balance Sheets at the end of the third quarter of
1998 and at the end of the year 1997................ 3
Statements of Operations for the third quarter
of 1998 and 1997.................................... 4
Statements of Operations for the first three quarters
of 1998 and 1997.................................... 5
Statements of Cash Flows for the first three quarters
of 1998 and 1997.................................... 6
Notes to Financial Statements.......................... 7-8
Item 2. Management's Discussion and Analysis of Results
of Operations and Financial Condition................... 9-13
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K........................ 14-17
Signatures....................................................... 14
</TABLE>
2
<PAGE>
MOORE MEDICAL CORP.
<TABLE>
<CAPTION>
Balance Sheets at end of
- --------------------------------------------------------------------------------
Amounts in thousands THIRD QUARTER 1998 YEAR 1997
(Unaudited)
- --------------------------------------------------------------------------------
ASSETS
<S> <C> <C>
CURRENT ASSETS
Cash $ 2,429 $ 54
Accounts receivable, less allowances
of $412 and $891......................... 12,582 15,212
Inventories................................. 13,202 13,416
Prepaid expenses and other current assets... 2,557 2,960
Deferred income taxes....................... 2,897 3,354
------- -------
Total Current Assets.................. 33,667 34,996
------- -------
NONCURRENT ASSETS
Equipment and leasehold improvements, net... 5,314 3,511
Other assets................................ 533 696
------- -------
Total Noncurrent Assets............... 5,847 4,207
------- -------
$39,514 $39,203
======= =======
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable............................ $ 7,276 $ 9,053
Accrued expenses............................ 6,961 5,801
------- -------
Total Current Liabilities............. 14,237 14,854
------- -------
DEFERRED INCOME TAXES.......................... 413 214
REVOLVING CREDIT FINANCING..................... -- 1,512
SHAREHOLDERS' EQUITY
Preferred stock - no shares outstanding..... -- --
Common stock - $.01 par value;
5,000 shares authorized;
3,248 shares issued...................... 33 32
Capital in excess of par value.............. 21,667 21,644
Retained earnings........................... 5,957 3,788
------- -------
27,657 25,464
Less treasury shares, at cost, 313 and 319
shares................................... (2,793) (2,841)
------- -------
Total Shareholders' Equity............ 24,864 22,623
------- -------
$39,514 $39,203
======= =======
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of the financial statements.
3
<PAGE>
MOORE MEDICAL CORP.
<TABLE>
<CAPTION>
Statements of Operations for the
- --------------------------------------------------------------------------------
Amounts in thousands, except per share data THIRD QUARTER
-------------------------------
1998 1997
(Unaudited)
- --------------------------------------------------------------------------------
<S> <C> <C>
Net sales................................... $32,529 $71,660
Cost of products sold....................... 22,322 60,066
------- -------
Gross profit................................ 10,207 11,594
Selling, general & administrative expenses.. 8,550 10,028
------- -------
Operating income............................ 1,657 1,566
Interest (income) expense, net.............. (19) 433
------- -------
Income before income taxes.................. 1,676 1,133
Income tax provision........................ 620 403
------- -------
Net income.................................. $ 1,056 $ 730
======= =======
Basic and Diluted Net Income Per Share...... $ .36 $ .25
======= =======
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of the financial statements.
4
<PAGE>
MOORE MEDICAL CORP.
<TABLE>
<CAPTION>
Statements of Operations for the
- --------------------------------------------------------------------------------
Amounts in thousands, except per share data FIRST THREE QUARTERS
--------------------------------
1998 1997
(Unaudited)
- --------------------------------------------------------------------------------
<S> <C> <C>
Net sales................................... $93,510 $229,740
Cost of products sold....................... 64,608 195,579
------- --------
Gross profit................................ 28,902 34,161
Selling, general & administrative expenses.. 25,501 30,625
------- --------
Operating income............................ 3,401 3,536
Interest (income) expense, net.............. (43) 1,472
------- --------
Income before income taxes.................. 3,444 2,064
Income tax provision........................ 1,274 738
------- --------
Net income.................................. $ 2,170 $ 1,326
======= ========
Basic and Diluted Net Income Per Share...... $ .74 $ .45
======= ========
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of the financial statements.
5
<PAGE>
MOORE MEDICAL CORP.
<TABLE>
<CAPTION>
Statements of Cash Flows for the
- --------------------------------------------------------------------------------
Amounts in thousands FIRST THREE QUARTERS
--------------------------
1998 1997
(Unaudited)
- --------------------------------------------------------------------------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net income............................. $ 2,170 $ 1,326
Adjustments to reconcile net income to
net cash flows provided by operating activities:
Depreciation and amortization......... 989 1,128
Deferred income taxes................. 656 212
Changes in operating assets and
liabilities:
Accounts receivable.................. 2,630 (2,970)
Inventories.......................... 214 9,340
Other current assets................. 403 (627)
Accounts payable..................... (1,777) (1,222)
Other current liabilities............ 1,330 (301)
------- -------
Net cash flows provided by
operating activities................ 6,615 6,886
------- -------
CASH FLOWS FROM INVESTING ACTIVITIES
Equipment and leasehold improvements.............. (2,792) ( 577)
------- -------
Net cash flows used in investing activities....... (2,792) (577)
------- -------
CASH FLOWS FROM FINANCING ACTIVITIES
Revolving credit financing (decrease), net...... (1,512) (6,438)
Other, net...................................... 64 118
------- -------
Net cash flows used in financing activities.. (1,448) (6,320)
------- -------
Increase/(decrease) in cash........................ 2,375 (11)
Cash at beginning of period........................ 54 16
------- -------
CASH AT END OF PERIOD.............................. $ 2,429 $ 5
======= =======
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of the financial statements.
6
<PAGE>
MOORE MEDICAL CORP.
NOTES TO FINANCIAL STATEMENTS
NOTE 1 - BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The accompanying financial statements should be read in conjunction with the
Notes to Financial Statements and Management's Discussion and Analysis of
Results of Operations and Financial Condition included in the Company's 1997
Annual Report filed on Form 10-K and in this Form 10-Q Report.
In the opinion of management, all adjustments necessary for a fair presentation
of the results for the interim periods have been made. The results of
operations for the third quarter and first three quarters are not necessarily
indicative of the results to be expected for the full year. The fiscal quarters
ended October 3, 1998 and September 27, 1997.
Certain prior year amounts have been reclassified to conform with the current
year presentation.
NOTE 2 - CONTINGENCIES
Beginning in 1991, the Company entered into various supply contracts with the
U.S. Department of Veterans Affairs and the Defense Department. In April 1997,
the Company completed a review of its compliance with various pricing provisions
of these contracts and, with the assistance of special legal counsel, concluded
that adjustments may be due to the federal agencies for potential unasserted
claims against the Company relating to pricing deficiencies under product supply
contracts subject to General Services Administration and Department of Defense
regulations. Management has assessed its estimated liability, and has commenced
discussions of the identified pricing issues with appropriate government
authorities. The ultimate resolution of this matter potentially could involve
purchase price adjustments and associated legal costs estimated to be $3.8
million. The Company established a reserve for this amount in December, 1996.
In management's opinion, the ultimate resolution of this matter will not have a
material adverse effect on the Company's financial position. Although
management believes that the reserve is sufficient, it is possible the final
resolution could exceed such reserve and could have a material impact on the
statement of operations and cash flow in such period.
7
<PAGE>
NOTE 3 - BASIC AND DILUTED NET INCOME PER SHARE
In the fourth quarter of 1997, the Company adopted Statement of Financial
Accounting Standards No. 128, "Earnings per Share," for all periods presented.
Basic earnings per share computations are determined based on the weighted
average number of shares outstanding during the period which was 2,933,000
shares and 2,924,000 shares in the third quarters of 1998 and 1997,
respectively, and 2,931,000 shares and 2,918,000 shares in the first three
quarters of 1998 and 1997, respectively. The effect of the exercise and
conversion of all securities, including stock options are included in the
diluted earnings per share calculation.
8
<PAGE>
MOORE MEDICAL CORP.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS
AND FINANCIAL CONDITION
OVERVIEW
- --------
The following table sets forth items included in the Statements of Operations as
a percentage of sales for the third quarter and first three quarters of 1998 and
1997, respectively. The table also shows, for each line item, the percentage
change in the 1998 periods from the comparable 1997 periods.
<TABLE>
<CAPTION>
THIRD QUARTER FIRST THREE QUARTERS
------------------------------------------ --------------------------------------
% of Sales % % of Sales %
---------------------------- ---------- ----------------------- -----------
1998 1997 Change 1998 1997 Change
------------- ----------- ---------- --------- --------- -----------
<S> <C> <C> <C> <C> <C> <C>
Net sales.......................... 100.0% 100.0% (55)% 100.0% 100.0% (59)%
Cost of products sold.............. 68.6 83.8 (63) 69.1 85.1 (67)
----- ----- ------ ------
Gross profit....................... 31.4 16.2 (12) 30.9 14.9 (15)
Selling, general & admin. exp...... 26.3 14.0 (15) 27.3 13.4 (17)
----- ----- ------ ------
Operating income................... 5.1 2.2 6 3.6 1.5 (4)
Interest (income)expense, net...... - 0.6 104 (0.1) 0.6 103
----- ----- ----- ------
Income before income taxes......... 5.1 1.6 48 3.7 0.9 67
Income tax provision............... 1.9 0.6 54 1.4 0.3 73
----- ----- ----- ------
Net income......................... 3.2% 1.0% 45% 2.3% 0.6% 64%
===== ===== ===== ===== ====== ======
</TABLE>
RESULTS OF OPERATIONS
- ----------------------
THIRD QUARTER
1998 COMPARED WITH 1997
- -----------------------
Net sales for the third quarter of 1998 decreased 55% to $32.5 million, compared
to $71.7 million in the same quarter a year ago. This decrease was primarily
due to the exiting of the wholesale drug distribution business in the fourth
quarter of 1997. Net sales in the wholesale drug distribution business
decreased $40.3 million while net sales in the healthcare practitioner business
increased $1.3 million or 4% in the quarter, compared to the same period in
1997.
For the quarter, gross profit dollars decreased 12% to $10.2 million. The
gross profit margin in the 1998 quarter increased to 31.4% of sales from 16.2%
in the same quarter a year ago. This increase is due to higher gross profit
margins in the healthcare practitioner business than in the wholesale drug
distribution business.
9
<PAGE>
Selling, general and administrative expenses during the third quarter of 1998
decreased 15% or $ 1.5 million, compared to the same quarter a year ago. The
decrease was primarily attributable to reductions in staff, freight expenses and
other expenses previously associated with the wholesale drug distribution
business.
Interest expense in the 1998 quarter has been reduced, compared with the same
quarter a year ago, by approximately $0.5 million, due to significant positive
cash flows resulting from the exiting of the wholesale drug distribution
business which have positioned the Company with no debt and positive cash flows
during the quarter.
Net income for the 1998 quarter increased 44.7%. The decrease in gross profit
was more than offset by decreases in selling, general and administrative expense
and interest expense. Net income was not significantly affected by any revenues
or expenses associated with the former wholesale drug distribution business.
FIRST THREE QUARTERS
1998 COMPARED WITH 1997
- -----------------------
Net sales for the first nine months of 1998 decreased 59% to $93.5 million from
$229.7 million in the first nine months of 1997. This decrease was primarily due
to the exiting of the wholesale drug distribution business in the fourth quarter
of 1997. Net sales of the wholesale drug distribution business decreased $146.2
million, while net sales of the healthcare practitioner business increased $9.4
million or 11% compared to the same period in 1997.
For the first nine months, gross profit dollars decreased 15.4% to $28.9
million. The gross profit margin rate increased in the first nine months of 1998
to 30.9% from 14.9% in the same period in 1997. Gross profit margins are higher
in the healthcare practitioner business than in the wholesale drug distribution
business.
Selling, general and administrative expenses during the first nine months of
1998 decreased 17% compared to the first nine months of 1997. The decrease is
primarily attributable to reductions of staff, freight expense and other
expenses related to the wholesale drug distribution business. In 1997, a pre-tax
charge of $0.8 million was recorded in connection with exiting various federal
government supply contracts.
Interest expense in the first nine months of 1998 has been reduced, compared
with the same period a year ago, by $1.5 million, due to significant positive
cash flows resulting from the exiting of the wholesale drug distribution
business which have positioned the Company with no debt and positive cash flows
during most of the first nine months of 1998.
10
<PAGE>
Net income for the first nine months increased 63.7% as compared to the same
period in 1997. The decrease in gross profit was more than offset by decreases
in selling, general and administrative expenses and interest expense. Net income
for the first nine months of 1998 was not significantly affected by revenues or
expenses of the former wholesale drug distribution business.
FINANCIAL CONDITION
- -------------------
During the first nine months of 1998 $6.6 million in funds provided by operating
activities were used to repay the remaining bank debt of $1.5 million, for
capital expenditures of $2.8 million and accounted for a $2.4 million increase
in cash. Operating activities generated $2.6 million from a decrease in accounts
receivable, $2.2 million from net income, $1.0 million from depreciation and
amortization, $0.7 million from deferred income taxes, $0.2 million from
decreased inventory and $1.7 million from a net change in other assets and
liabilities. Operating activities used cash of $1.8 million to reduce accounts
payable. The change in accounts receivable was primarily due to the collection
of accounts in connection with exiting the wholesale drug distribution business.
The Company's bank financing agreement, under which no debt was outstanding
during the third quarter, provides for a $10 million revolving line of credit
through December, 1999. The facility provides for funding limited by a formula
using accounts receivable balances and inventory levels as the primary
variables. Interest on loans is charged at the prime rate or, at the option of
the Company, at the Eurodollar rate plus a rate in the range of 1% to 2%
depending on the financial leverage of the Company. In addition, the Company
pays a 1/4% commitment fee on the unused line of credit. Substantially all of
the assets of the Company have been pledged as collateral and the agreement
contains covenants and restrictions relating to asset protection, financial
condition, dividends, investments, acquisitions and certain other matters.
Management believes that the funding needs of the Company for operating working
capital, capital expenditures and possible acquisitions will be met through cash
flow from operations and financing sources.
YEAR 2000 COMPLIANCE
- --------------------
"Year 2000" issues are the result of computer programs that were written using
two digits rather than four to define the applicable year. If the Company's
computer programs with date sensitive functions are not Year 2000 compliant,
they may recognize a date using "00" as the year 1900 rather than the year 2000.
This could result in a system failure or miscalculations causing disruptions of
operations, including, an inability to process transactions, send invoices or
engage in other normal business activities.
The Company has identified its Year 2000 risk in three categories: internal
business software, internal non-information technology software and external
vendor compliance.
11
<PAGE>
Internal Information Technology
- -------------------------------
During 1998, as part of a modernization program intended to improve productivity
and increase profitability by upgrading data processing, integrating systems and
enhancing internal reporting, the Company purchased an integrated enterprise
system which includes software which the vendor has represented to be Year 2000
compliant. The total estimated hardware, software, installation and training
cost of the integrated enterprise system, of which Year 2000 compliance is a by-
product, is $4.5 million of which $1.9 million has been incurred to date, funded
through operating cash flow. The Company is in the implementation phase for
this system, with full implementation scheduled for mid-1999. Based on this
schedule, the Company plans its internal information technology systems to be in
substantial compliance before the year 2000. However, if due to unforeseen
circumstances, the implementation is not completed in a timely manner, Year 2000
issues could have a material adverse impact on the Company's operations,
liquidity and financial condition. Contingency plans are being developed for
areas where management considers there may be some risk to modify certain of the
major existing internal information technology systems to be Year 2000
compliant.
Internal Non-Information Technology
- -----------------------------------
The Company plans to assess the Year 2000 compliance of its internal non-
information software and of the technology embedded in such systems as security,
telecommunications and building systems by contacting the providers of such
systems by mid-1999. Since the Company is in the information gathering phase,
it does not have sufficient data to estimate the scheduling or costs of
achieving Year 2000 compliance for such systems or have a contingency plan in
place therefore.
External Vendor Compliance
- --------------------------
The Company is in the process of identifying and contacting its major suppliers,
service providers and contractors ("vendors") to determine the extent of their
Year 2000 compliance. It plans that the process will be completed by mid-1999.
To the extent that responses are unsatisfactory, the Company intends to
consider changing its major vendors to those who have represented Year 2000
readiness, but cannot be assured that it will be successful in finding
alternative vendors. In the event that major vendors are not Year 2000
compliant and the Company does not replace them with new vendors, its business
could be materially adversely affected. The Company plans to consider
formulating a contingency plan for major vendors' Year 2000 non-compliance in
mid-1999, after it receives responses from vendors.
12
<PAGE>
FORWARD-LOOKING INFORMATION
- ---------------------------
From time to time, the Company or its representatives may have made or may make
forward-looking statements, orally or in writing. Such forward-looking
statements may be included in, but, not limited to, press releases, oral
statements made by or with the approval of an authorized executive officer, or
in this report or other filings made by the Company with the Securities and
Exchange Commission. The words or phrases "trend," "expect," "grow," "will,"
"could," "likely result," "planned," "continued," "anticipated," "estimated,"
"projected," "scheduled," "could have," "intended," or similar expressions are
intended to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. The Company wishes to ensure
that such statements are accompanied by meaningful cautionary statements, so as
to maximize to the fullest extent possible the protections of the safe harbor
established in the said Act. Accordingly, such statements are qualified in
their entirety by reference to and are accompanied by the following discussion
of certain important factors that could cause actual results to differ
materially from such forward-looking statements.
Investors should also be aware of factors that could have an impact on the
Company's business or financial position or performance. These include
possible: pressures on revenues resulting, for example, from customer
consolidations or changes in customer buying patterns; intensified competition
resulting, for example, from distributor consolidations or pricing pressures
from distributors able to benefit from economies of scale or other operating
efficiencies; disruptions in services or systems on which the Company is
dependent, such as by truckers in deliveries from its suppliers, by UPS or other
common carriers in deliveries to its customers, by its catalog printers or in
telecommunication services, or relating to its computer systems or Year 2000
issues (including regarding costs, scheduling, implementation, vendor
compliance, and plans and expectations regarding such); unfavorable outcomes of
litigation to which the Company may become a party; and other factors detailed
from time to time in the Company's Securities and Exchange Commission filings or
other readily available or generally disseminated writings. The risks
identified here are not all inclusive. Reference is also made to other parts of
this report and the Company's most recent Annual Report on Form 10-K that
include additional information concerning factors that could adversely impact
the Company's business or financial position or performance. Moreover, the
Company operates in a changing and very competitive business environment. New
risks may emerge from time to time, and it is not possible for management to
predict all risk factors, nor can it necessarily identify or assess the impact
of all such factors on the Company or the extent to which any factor or
combination of factors may cause actual results to differ materially from those
contained in any forward-looking statements. Accordingly, forward-looking
statements should not be relied upon as a prediction of actual results.
13
<PAGE>
PART II. OTHER INFORMATION
-----------------
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
--------------------------------
(a) Exhibits
--------
Certificate of Correction, pursuant to Section 103 (f) of the
Delaware General Corporation Law, dated November 10, 1998 -
Exhibit 3.2A
(b) Reports on Form 8-K
-------------------
No report on Form 8-K was filed during the quarter.
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
MOORE MEDICAL CORP.
(REGISTRANT)
By: /s/ David V. Harper By: /s/ Susan G. D'Amato
----------------------------------- ------------------------------
David V. Harper Susan G. D'Amato
Vice President - Finance and Controller and Chief
Chief Financial Officer Accounting Officer
November 10, 1998 November 10, 1998
14
<PAGE>
Exhibit 3.2A
CERTIFICATE OF CORRECTION
OF
MOORE MEDICAL CORP.
-----------------------------------------
Pursuant to Section 103(f) of the General
Corporation Law of the State of Delaware
-----------------------------------------
I, Mark Karp, President of Moore Medical Corp., a corporation organized and
existing under the General Corporation Law of the State of Delaware (the
"Corporation"), in accordance with the provisions of Section 103(f) of such law,
DO HEREBY CERTIFY that:
1. The Certificate of Amendment of Certificate of Incorporation of the
Corporation filed with the Secretary of State of the State of Delaware on June
30, 1981 (the "June 30, 1981 Amendment") inadvertently set forth an inaccurate
record of the corporate action therein referred to.
2. Paragraph FIRST of the June 30, 1981 Amendment should be corrected by
deleting the words "By striking out the whole of Article FOURTH thereof as it
now exists and inserting in lieu and instead thereof a new Article FOURTH,
reading as follows: "in the second paragraph of Paragraph FIRST of the June 30,
1981 Amendment and replacing such words with the following: "By deleting the
first full paragraph of Article Fourth thereof and substituting the following:".
15
<PAGE>
3. This Certificate of Correction shall not be deemed to amend or correct (a)
any other provision of the June 30, 1981 Amendment or (b) any certificate of
amendment of the Corporation's Certificate of Incorporation or certificate of
designations of the Corporation filed with the Secretary of State of the State
of Delaware at any time after June 30, 1981.
IN WITNESS WHEREOF, I have executed and subscribed this Certificate of
Correction and do affirm the foregoing as true under the penalties of perjury
this 6th day of November, 1998.
/s/ Mark Karp
---------------------------------
Mark Karp
President
ATTEST:
/s/ Joseph Greenberger
- ------------------------------------
Joseph Greenberger
Secretary
16
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JAN-02-1999
<PERIOD-START> JUL-05-1998
<PERIOD-END> OCT-03-1998
<CASH> 2,429
<SECURITIES> 0
<RECEIVABLES> 12,994
<ALLOWANCES> 412
<INVENTORY> 13,202
<CURRENT-ASSETS> 33,667
<PP&E> 15,899
<DEPRECIATION> (10,585)
<TOTAL-ASSETS> 39,514
<CURRENT-LIABILITIES> 14,237
<BONDS> 0
0
0
<COMMON> 33
<OTHER-SE> 24,831
<TOTAL-LIABILITY-AND-EQUITY> 39,514
<SALES> 32,529
<TOTAL-REVENUES> 32,529
<CGS> 22,322
<TOTAL-COSTS> 22,322
<OTHER-EXPENSES> 8,550
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (19)
<INCOME-PRETAX> 1,676
<INCOME-TAX> 620
<INCOME-CONTINUING> 1,056
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,056
<EPS-PRIMARY> 0.36
<EPS-DILUTED> 0.36
</TABLE>
